Area of action


As an emerging global health threat, the mosquito-borne chikungunya virus has spread throughout Africa, Asia, Oceania, the Americas, and Europe, affecting millions of people.

Our preparedness work

In early 2018, the GloPID-R Chikungunya (CHIKV), O’nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group was formed to identify knowledge gaps and to propose recommendations for research funders, direct future investigations and suggest rectification measures.

Working group

The working group brought together some 30 experts from across the globe. Their areas of focus included diagnostics, epidemiology, clinical treatment, monitoring and vector control.

A total of 22 organizations took part in the working group, which published its final reports in late 2019. Working group participants included:

  • Aix-Marseille university-IRD-INSERM-IHU (France)
  • Fiocruz (Brazil)
  • University of Glasgow (UK)
  • University of Pereira (Colombia)
  • Institut Pasteur of Dakar (Senegal)
  • Institut Pasteur of Paris (France)
  • Institut Pasteur of Guadeloupe
  • Institut Pasteur of Cambodia
  • Centre for infectious disease control (Rotterdam, the Netherlands)
  • Stanford University (USA)
  • French Military Medical Service (Marseille, France)
  • Blood Systems Research Institute (San Francisco, USA)
  • University of Berlin (Germany)
  • University of Leuven (Belgium)
  • A*STAR (Singapore)
  • Food and Drug Administration (Washington, D.C., USA)
  • Public Health Agency of Canada (Winnipeg, Canada)
  • Washington University (St. Louis, USA)
  • Blood Systems Research Institute (San Francisco, USA)
  • University of Texas Medical Branch (Galveston, USA)
  • Etablissement Français du Sang (Marseille, France)
  • Heidelberg University Hospital (Germany)


EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094188.